Fat-Derived cell therapy could offer new hope for thumb arthritis

NCT ID NCT05915962

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study examines nanofat—a processed form of a person's own fat—to see if it could be used as a cell therapy for rhizarthrosis, a common and painful form of thumb osteoarthritis. Researchers will collect fat samples from healthy volunteers and analyze the cells and sterility in the lab. The goal is to understand the biological makeup of nanofat before testing it as a treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Nanofat autograft (emulsified fat tissue containing mesenchymal stromal cells)
What this could lead to
If successful, this biological characterization could pave the way for using nanofat as a cell therapy to treat thumb osteoarthritis, potentially reducing pain and improving function without surgery.
What could go wrong
This is a very early, small study focused only on lab analysis of the nanofat, not on treating patients. It may not lead to an effective therapy, and the preparation method may not produce consistent results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHIZARTHROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Privé Paul d'Egine

    Champigny-sur-Marne, 94500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.